| MeSH term | MeSH ID | Detail |
|---|---|---|
| Respiratory Tract Infections | D012141 | 4 associated lipids |
| Agammaglobulinemia | D000361 | 4 associated lipids |
| Corneal Edema | D015715 | 3 associated lipids |
| Tuberculosis, Pulmonary | D014397 | 18 associated lipids |
| HIV Seropositivity | D006679 | 15 associated lipids |
| Endophthalmitis | D009877 | 12 associated lipids |
| Enteritis | D004751 | 8 associated lipids |
| Leprosy | D007918 | 8 associated lipids |
| Periapical Periodontitis | D010485 | 6 associated lipids |
| Bronchial Hyperreactivity | D016535 | 15 associated lipids |
Azithramycine
Azithramycine is a lipid of Polyketides (PK) class. Azithramycine is associated with abnormalities such as Respiratory Tract Infections, Pneumonia, Lower respiratory tract infection, Infection and Nonspecific urethritis. The involved functions are known as Lysis, Selection, Genetic, Mutation, Relapse and Adaptation. Azithramycine often locates in Blood, Respiratory System, Genitourinary system, Back and Chest. The associated genes with Azithramycine are Genes, rRNA, Genome, RPL22 gene, OPRM1 gene and tryptic soy broth. The related lipids are Liposomes, Phosphatidylserines, Promega, Lipopolysaccharides and Steroids. The related experimental models are Mouse Model, Knock-out and Tissue Model.
Cross Reference
Introduction
To understand associated biological information of Azithramycine, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.
What diseases are associated with Azithramycine?
Azithramycine is suspected in Infection, Pneumonia, Trachoma, Respiratory Tract Infections, Gonorrhea, Infectious disease of lung and other diseases in descending order of the highest number of associated sentences.
Related references are mostly published in these journals:
- Antimicrob. Agents Chemother. (156)
- Clin. Infect. Dis. (64)
- J. Antimicrob. Chemother. (50)
- Others (435)
| Disease | Cross reference | Weighted score | Related literature |
|---|
Loading... please refresh the page if content is not showing up.
Possible diseases from mapped MeSH terms on references
We collected disease MeSH terms mapped to the references associated with Azithramycine
PubChem Associated disorders and diseases
What pathways are associated with Azithramycine
There are no associated biomedical information in the current reference collection.
PubChem Biomolecular Interactions and Pathways
Link to PubChem Biomolecular Interactions and PathwaysWhat cellular locations are associated with Azithramycine?
Visualization in cellular structure
Associated locations are in red color. Not associated locations are in black.
Related references are published most in these journals:
- Antimicrob. Agents Chemother. (66)
- J. Antimicrob. Chemother. (25)
- Clin. Infect. Dis. (13)
- Others (151)
| Location | Cross reference | Weighted score | Related literatures |
|---|
Loading... please refresh the page if content is not showing up.
What functions are associated with Azithramycine?
Related references are published most in these journals:
| Function | Cross reference | Weighted score | Related literatures |
|---|
What lipids are associated with Azithramycine?
Related references are published most in these journals:
| Lipid concept | Cross reference | Weighted score | Related literatures |
|---|
Loading... please refresh the page if content is not showing up.
What genes are associated with Azithramycine?
Related references are published most in these journals:
- Antimicrob. Agents Chemother. (44)
- J. Antimicrob. Chemother. (18)
- Clin. Infect. Dis. (10)
- Others (126)
| Gene | Cross reference | Weighted score | Related literatures |
|---|
What common seen animal models are associated with Azithramycine?
Mouse Model
Mouse Model are used in the study 'Azithromycin increases in vitro fibronectin production through interactions between macrophages and fibroblasts stimulated with Pseudomonas aeruginosa.' (Cory TJ et al., 2013), Mouse Model are used in the study 'Efficacy of azithromycin, clarithromycin and beta-lactam agents against experimentally induced bronchopneumonia caused by Haemophilus influenzae in mice.' (Miyazaki S et al., 2001), Mouse Model are used in the study 'Oral anti-pneumococcal activity and pharmacokinetic profiling of a novel peptide deformylase inhibitor.' (Gross M et al., 2004), Mouse Model are used in the study 'Inhibition of quorum sensing in Pseudomonas aeruginosa by azithromycin and its effectiveness in urinary tract infections.' (Bala A et al., 2011) and Mouse Model are used in the study 'Enhanced efficacy of single-dose versus multi-dose azithromycin regimens in preclinical infection models.' (Girard D et al., 2005).
Knock-out
Knock-out are used in the study 'Influence of rhlR and lasR on Polymyxin Pharmacodynamics in Pseudomonas aeruginosa and Implications for Quorum Sensing Inhibition with Azithromycin.' (Bulman ZP et al., 2017) and Knock-out are used in the study 'Azithromycin in Pseudomonas aeruginosa biofilms: bactericidal activity and selection of nfxB mutants.' (Mulet X et al., 2009).
Tissue Model
Tissue Model are used in the study 'Development of a population pharmacokinetic model characterizing the tissue distribution of azithromycin in healthy subjects.' (Zheng S et al., 2014).
Related references are published most in these journals:
| Model | Cross reference | Weighted score | Related literatures |
|---|
Loading... please refresh the page if content is not showing up.
NCBI Entrez Crosslinks
All references with Azithramycine
Download all related citations| Authors | Title | Published | Journal | PubMed Link |
|---|---|---|---|---|
| Rivero-Sánchez L et al. | Fitz-Hugh-Curtis syndrome: abdominal pain in women of 26 years old. | 2011 | Rev Esp Enferm Dig | pmid:22054272 |
| de Górgolas Hernández-Mora M et al. | [Therapeutic approaches to cryptosporidiosis. A review of the literature]. | 1993 | Rev Clin Esp | pmid:8259458 |
| Cofré Guerra J | [Pertussis chemoprophylaxis: a sterile effort?]. | 2006 | Rev Chilena Infectol | pmid:16462967 |
| RuÃz del Olmo I et al. | [Severe neutropenia as side effect of medical treatment in nontuberculous mycobacterial adenitis]. | 2015 | Rev Chilena Infectol | pmid:26633119 |
| Aires FT et al. | Efficacy of azithromycin on the treatment of syphilis. | 2010 Sep-Oct | Rev Assoc Med Bras (1992) | pmid:21152813 |
| Bowen BE et al. | Diagnostic and therapeutic challenges. | 2011 | Retina (Philadelphia, Pa.) | pmid:21866076 |
| Khairallah M et al. | Acute choroidal ischemia associated with toxoplasmic retinochoroiditis. | 2007 | Retina (Philadelphia, Pa.) | pmid:17891022 |
| Soepandi P et al. | The pattern of micro-organisms and the efficacy of new macrolide in acute lower respiratory tract infections. | 1998 | Respirology | pmid:9692520 |
| Diego AD et al. | Effects of long-term azithromycin therapy on airway oxidative stress markers in non-cystic fibrosis bronchiectasis. | 2013 | Respirology | pmid:23714268 |
| Karabay O | Is azithromycin prophylaxis a rational approach for bronchoscopic biopsy? | 2007 | Respirology | pmid:17587436 |
| Singh N | All generalizations are false including this one. | 2007 | Respirology | pmid:17587437 |
| Hodge S et al. | Increased CD8 T-cell granzyme B in COPD is suppressed by treatment with low-dose azithromycin. | 2015 | Respirology | pmid:25308201 |
| Lourdesamy Anthony AI and Muthukumaru U | Efficacy of azithromycin in the treatment of bronchiectasis. | 2014 | Respirology | pmid:25183304 |
| Kanazawa H | Efficacy of azithromycin administration in prevention of respiratory tract infection after bronchoscopic biopsy: a randomized, controlled trial. | 2007 | Respirology | pmid:17207028 |
| Smith DJ et al. | Pseudomonas aeruginosa antibiotic resistance in Australian cystic fibrosis centres. | 2016 | Respirology | pmid:26711802 |
| Wong C and Jones S | Oxidative stress and macrolides in bronchiectasis--exhaling few clues. | 2013 | Respirology | pmid:23890203 |
| Hansbro PM and Jarnicki AG | Macrolides for macrophages in chronic obstructive pulmonary disease. | 2012 | Respirology | pmid:22563902 |
| Hodge S and Reynolds PN | Low-dose azithromycin improves phagocytosis of bacteria by both alveolar and monocyte-derived macrophages in chronic obstructive pulmonary disease subjects. | 2012 | Respirology | pmid:22288725 |
| Hanon S et al. | Evidence of improved small airways function after azithromycin treatment in diffuse panbronchiolitis. | 2012 | Respiration | pmid:22759949 |
| Kawamura K et al. | Efficacy of azithromycin for treatment of acute exacerbation of chronic fibrosing interstitial pneumonia: a prospective, open-label study with historical controls. | 2014 | Respiration | pmid:24802885 |
| Ballard HO et al. | Azithromycin in the extremely low birth weight infant for the prevention of bronchopulmonary dysplasia: a pilot study. | 2007 | Respir. Res. | pmid:17550598 |
| Persson HL et al. | Leaky lysosomes in lung transplant macrophages: azithromycin prevents oxidative damage. | 2012 | Respir. Res. | pmid:23006592 |
| Ra SW et al. | Azithromycin and risk of COPD exacerbations in patients with and without Helicobacter pylori. | 2017 | Respir. Res. | pmid:28558695 |
| Beigelman A et al. | Azithromycin attenuates airway inflammation in a mouse model of viral bronchiolitis. | 2010 | Respir. Res. | pmid:20591166 |
| Berkhof FF et al. | Azithromycin and cough-specific health status in patients with chronic obstructive pulmonary disease and chronic cough: a randomised controlled trial. | 2013 | Respir. Res. | pmid:24229360 |
| Lendermon EA et al. | Azithromycin decreases NALP3 mRNA stability in monocytes to limit inflammasome-dependent inflammation. | 2017 | Respir. Res. | pmid:28659178 |
| Legssyer R et al. | Azithromycin reduces spontaneous and induced inflammation in DeltaF508 cystic fibrosis mice. | 2006 | Respir. Res. | pmid:17064416 |
| Niederman MS et al. | Eradication of H. influenzae in AECB: A pooled analysis of moxifloxacin phase III trials compared with macrolide agents. | 2006 | Respir Med | pmid:16531032 |
| Haworth CS et al. | Long-term macrolide maintenance therapy in non-CF bronchiectasis: evidence and questions. | 2014 | Respir Med | pmid:25301290 |
| Samson C et al. | Long-term effects of azithromycin in patients with cystic fibrosis. | 2016 | Respir Med | pmid:27492507 |
| Equi AC et al. | Exploring the mechanisms of macrolides in cystic fibrosis. | 2006 | Respir Med | pmid:16185859 |
| DeAbate CA et al. | The safety and efficacy of short course (5-day) moxifloxacin vs. azithromycin in the treatment of patients with acute exacerbation of chronic bronchitis. | 2000 | Respir Med | pmid:11127487 |
| Cazzola M et al. | Treatment of acute exacerbation of severe-to-very severe COPD with azithromycin in patients vaccinated against Streptococcus pneumoniae. | 2005 | Respir Med | pmid:15878482 |
| Anwar GA et al. | Effects of long-term low-dose azithromycin in patients with non-CF bronchiectasis. | 2008 | Respir Med | pmid:18653323 |
| Steinkamp G et al. | Once-weekly azithromycin in cystic fibrosis with chronic Pseudomonas aeruginosa infection. | 2008 | Respir Med | pmid:18701270 |
| Simoens S et al. | Preventing COPD exacerbations with macrolides: a review and budget impact analysis. | 2013 | Respir Med | pmid:23352223 |
| de Wall C et al. | Home spirometry as early detector of azithromycin refractory bronchiolitis obliterans syndrome in lung transplant recipients. | 2014 | Respir Med | pmid:24445061 |
| Naderi N et al. | Long-term azithromycin therapy to reduce acute exacerbations in patients with severe chronic obstructive pulmonary disease. | 2018 | Respir Med | pmid:29724384 |
| Kamio K and Azuma A | Diffuse panbronchiolitis: A fine road from the discovery of a disease to the establishment of treatment. | 2018 | Respir Investig | pmid:30049592 |
| Wan YF et al. | Azithromycin attenuates pulmonary inflammation and emphysema in smoking-induced COPD model in rats. | 2015 | Respir Care | pmid:25249648 |
| Escudero E et al. | Pharmacokinetics and tissue tolerance of azithromycin after intramuscular administration to rabbits. | 2006 | Res. Vet. Sci. | pmid:16530237 |
| Ramalho VL et al. | Comparison of azithromycin and oral hygiene program in the treatment of cyclosporine-induced gingival hyperplasia. | 2007 | Ren Fail | pmid:17497438 |
| Krásny J et al. | The role of Chlamydia pneumoniae in the etiology of keratoconjunctivitis sicca (KCS). | 2014 | Recent Pat Inflamm Allergy Drug Discov | pmid:25395268 |
| Debremaeker D et al. | Analysis of unknown compounds in azithromycin bulk samples with liquid chromatography coupled to ion trap mass spectrometry. | 2003 | Rapid Commun. Mass Spectrom. | pmid:12569445 |
| Zhou F et al. | High accuracy mass measurement of peptides with internal calibration using a dual electrospray ionization sprayer system for protein identification. | 2002 | Rapid Commun. Mass Spectrom. | pmid:11870887 |
| Bascones-Martinez A et al. | Prevention of alveolar osteitis with azithromycin in women according to use of tobacco and oral contraceptives. | 2007 | Quintessence Int | pmid:17432784 |
| Kikuchi Y et al. | Hyperoxia exaggerates bacterial dissemination and lethality in Pseudomonas aeruginosa pneumonia. | 2009 | Pulm Pharmacol Ther | pmid:19162211 |
| Mertens TC et al. | Azithromycin differentially affects the IL-13-induced expression profile in human bronchial epithelial cells. | 2016 | Pulm Pharmacol Ther | pmid:27246785 |
| Blasi F et al. | Long-term azithromycin use in patients with chronic obstructive pulmonary disease and tracheostomy. | 2010 | Pulm Pharmacol Ther | pmid:20025989 |
| Kai T et al. | A low concentration of azithromycin inhibits the mRNA expression of N-acyl homoserine lactone synthesis enzymes, upstream of lasI or rhlI, in Pseudomonas aeruginosa. | 2009 | Pulm Pharmacol Ther | pmid:19393329 |